||Post-surgical pain, dental pain, gout, etc.; to be broadened as supported by relevant data and regulatory filings to include all incidences of acute pain.
||ATB-352 is a hydrogen sulfide-releasing derivative of ketoprofen, a potent non-sterioidal anti-inflammatory drug (“NSAID”) commonly prescribed for acute pain.
|TARGET SEGMENT(S) AND MARKETPLACE
||Opioids (such as fentanyl and OxyContin) are commonly prescribed for acute pain relief, yet their use is associated with abuse due to their highly addictive nature. There is an urgent need for a safer, non-addictive pain-killer for severe pain in the wake of a surge in drug overdose deaths related to opioid abuse. According to the Centre for Disease Control and Prevention (CDC), more than 60% of drug overdose deaths involve an opioid (including prescription opioids and heroin), and the number of overdose deaths involving opioids have quadrupled since 1999.
||Antibe recently confirmed the non-addictive properties of ATB-352, a more potent NSAID, targeting the significant market for severe, acute pain. In addition, pre-clinical studies have demonstrated that ATB-352 caused negligible GI damage compared to ketoprofen.
||Due to its intended short-term use for acute pain, Antibe anticipates that the development timeline will be considerably accelerated as compared to that for a chronic-use drug such as ATB-346. Antibe expects to conclude IND-enabling pre-clinical studies for ATB-352 in 2020.